Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,901–2,000 of 2,039
Demırcan, F., Özozan, Ö. V., & Gözel, N. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02422-8
“Larger prospective studies with longer follow-up and comprehensive biomarker assessment are warranted [5, 11–14”
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Li, Y., Ye, D., Fu, C., Huang, X., Ma, Q., Zhang, F., Chen, G., Song, P., Kong, C., Wu, J., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2687937
“30 On the other hand, pharmacological or genetic inhibition of GIP signaling induces weight loss in preclinical models, potentially through attenuation of adipogenic signaling and modulation of central energy balance.”
Pedicino, D., & Liuzzo, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag550
Rodriguez, P. J., Lusk, J. B., Mehta, H. B., Levy, J. F., Kalogeropoulos, A. P., Soneji, S., Do, D., Holler, E., Webber, E., Gluckman, T., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-109259 · Cited by 2
“17–19 While these metabolic effects are not directly related to alcohol use, they may reflect broader effects on reward pathways and appetite regulation that could also influence alcohol consumption and related outcomes.”
Li, J., Li, J., Xu, X., Wang, N., Lu, Y., & Wang, B. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03304-y
“In clinical trials, tirzepatide, a dual GIPR/GLP1R agonist, has shown greater reductions in plasma glucose and body weight than GLP1R agonist alone [12, 13].”
Xu, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71138 · Cited by 2
Antor, S. A., Mahjabin, & Jewel, G. M. N. A. (2026) · Research Square · doi:10.21203/rs.3.rs-10159812/v2
Gomon, Y. М., Колбин, А. С., Spichakova, E. A., & Reznik, V. A. (2026) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-gcp-0022
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Singla, A., Kaur, G., Singh, G., Luthra, S., Lodha, C., Alneser, O., Alo, M. S., Ali, S. K. S., & Zulqarnain, M. A. (2026) · Cureus · doi:10.7759/cureus.113371
“Tirzepatide, the first approved dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist [6], demonstrated superior weight reduction versus semaglutide in the SURPASS-2 and SURMOUNT-5 trials, with cardiovascular outcomes data from SURPASS-CVOT awaited [7,8].”
Shegena, E. A., Kiflu, M., Ahmed, M. B., Bhagavathula, A. S., & Abegaz, T. M. (2026) · Obesity Reviews · doi:10.1111/obr.70200
Varra, F., Theodosis‐Nobelos, P., Varra, V., & Varras, M. N. (2026) · Medicina · doi:10.3390/medicina62081445
Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes
Mega, A., Aigner, E., Turri, C., Vittadello, F., Dauriz, M., Floreani, A., Marzi, L., Sacco, R., & Stasi, C. (2026) · Minerva Medica · doi:10.23736/s0026-4806.26.09922-2
Dei, A., Aldigeri, R., Maglietta, G., Balestreri, E., Garofolo, M., Daniele, G., Penno, G., Trombetta, M., Csermely, A., Antonini, M., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02930-3
de Assis, D. C. M., Coelho, F. M. M., de Melo, P. M., & dos Santos, D. W. (2026) · Research Society and Development · doi:10.33448/rsd-v15i7.51433
Exploring on the Hyperinsulinism Management in Women with Polycystic Ovary Syndrome
de Medeiros, S. F., Yamamoto, M. M. W., Jacomeli, J., Soares, J. M., Maciel, G. A. R., & Baracat, E. C. (2026) · Journal of Gynecology and Obstetrics · doi:10.11648/j.jgo.20261403.12
Rivera‐Gonzalez, O., Liu, L., Gribble, F. M., Reimann, F., & Wess, J. (2026) · Science Advances · doi:10.1126/sciadv.aeb9805
“The first member of this class of drugs is tirzepatide, which has been approved by the US Food and Drug Administration for the treatment of T2D and obesity ( 16 – 18 ).”
Malviya, V. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00050
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Wang, L., Jiang, F., Yuan, S., Sun, J., Zhao, J., Zhou, S., Liang, J., Li, H., Song, P., Wang, S., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156711
“2, Supplementary Table 6, 7).”
Zhang, S., Liu, S., Zhou, M., Wang, J., Zhang, Y., Zhong, H., & Ning, G. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06090-6
“Notably, tirzepatide has exhibited better clinical efficacy than sema-glutide in diabetes trials [73].”
Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review
Garcia, C. C., Moryousef, J., Pinthus, J. H., & Leong, D. P. (2026) · Cancers · doi:10.3390/cancers18152465
Acute pancreatitis and its impact on mental health
Hoard, M., & Smith, Z. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00004-x
Luo, Y., Xia, J., Yao, X., Jahed, S. A., Bee, Y. M., Chen, L., Chan, S. P., Deerochanawong, C., Alice Pik Shan, K. O. N. G., Nguyen, K. T., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113474
Agonists and Antagonists of the Human GIP Receptor
Kizilkaya, H. S., Gasbjerg, L. S., Holst, J. J., & Rosenkilde, M. M. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch2
The Role of Gut Peptides in the Regulation of Body Weight
Holst, J. J., & Madsbad, S. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch1
Ferreira, M. H. L., Câmara, L. C., Mattoso, S. O., Pereira, S. I. D. S., de Aguiar, D. R., & Khan, Z. U. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02580-9
“…persist regarding the true magnitude and durability of the effects, the dose–response relationship, and the balance between efficacy and toler - ability, particularly with respect to gastrointestinal adverse events, treatment discontinuation, and potential glucagon-mediated effects [ 13, 18].”
GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures
Barnaba, I., Massari, F., Ciccone, M. M., Caldarola, P., Campanella, C., Ricci, G., & Scicchitano, P. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2714849
Mahmood, A., Sehar, N. U., Farooq, A., Latif, S., Rasul, M., Abbasi, S., Ali, A. M., Arshad, E., Malik, M. A., Nenwani, K., et al. (2026) · F1000Research · doi:10.12688/f1000research.186694.1
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
Impact of glucagon-like peptide-1 receptor agonists on bone metabolism
Vadini, V., Duan, D., & Moseley, K. F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag323 · Cited by 2
GLP-1-based multipharmacology: Biased signaling as a determinant of therapeutic efficacy
Li, W., Yan, J., Zhao, F., & Yang, D. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.07.001
Tsvetkova, V. V., & Todorova, K. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167083
Mechanism of action: Glucagon-like peptide-1 receptors in skin biology
Mehta, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.004
Vignera, S. L., & Condorelli, R. A. (2026) · Medicina · doi:10.3390/medicina62081536
“Tirzepatide, a dual GIP/GLP-1 receptor agonist with a half-life of approximately 5 days [5], has demonstrated even greater efficacy in the SURPASS trial series, with HbA1c reductions of up to 2.3% and weight loss exceeding 20% in some patient populations [6–8].”
InfluentialKhalil, I., Hossain, M. I., Akter, M. M., Wahid, F., Khalid, A. A., Promi, S. A., Sayed, M. A., Rahman, M. T., & Sarker, P. (2026) · Clinical Cardiology · doi:10.1002/clc.70441
“Head‐to‐head trials in T2DM (e.g., SURPASS‐1, SURPASS‐2) have shown tirzepatide's superior HbA1c reduction and weight loss [11, 17].”
Goryanin, I., Damms, B., & Goryanin, I. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70322 · Cited by 1
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Valdez, Y., Segev, N., Parimi, N., Vegesna, M., Brown, E. A., Samuels, S. L., Name, M. A. V., SHAH, A. S., & Wolf, R. M. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0335
“In SURPASS-PEDS, tirzepatide reduced A 1C by 2.23 percentage points at 30 weeks, and in SURPASS-2, adults receiving tirzepatide had A 1C reductions of approximately 2.0 – 2.3 percentage points, exceeding the e ff ects associated with sem-aglutide 1 mg [7, 12].”
InfluentialBeyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
Fischer, S. L., & Borner, T. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108382
Dedanishvili, N. S., Pyurveev, S. S., Brus, T. V., & Vasiliev, A. G. (2026) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2026-11.3.20
Ahmed, Z., Mustafa, N., Sarkar, T., & Yasmin, H. (2026) · Health Science Reports · doi:10.1002/hsr2.73044
“The synergistic activation of GLP‐1 and GIP receptors ultimately results in potent systemic metabolic effects, including substantial weight reduction, improved glycemic control, and favorable alterations in lipid metabolism [16].”
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review
Abdalla, S. A. M., Gharbawi, L., Elshaikh, N., Omer, E. O. E., Osman, A. F. M., Ali, A. S. H., Mohamed, T. M. Y., & Alhajri, A. H. M. (2026) · Cureus · doi:10.7759/cureus.114454
“For several years the only head-to-head randomised evidence was SURPASS-2, in which tirzepatide produced greater reductions in both glycated haemoglobin (HbA1c) and body weight than semaglutide [10].”
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 3
Terrell, K. A., Lage, M. J., Valentine, W. J., Paik, J. S., & Boye, K. S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03753-7
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7
“First, head-to-head trials such as SURPASS-2 have confirmed that tirzepatide induces significantly greater weight loss than semaglutide [ 62 ], providing a stronger physiological basis for BP reduction.”
Alharajin, R., AlTaweel, M., AlSubaiee, M., Almekhloof, S., Almusaad, A., Alarfaj, A. A., Alkhayyal, A. K., Altharman, N. M., Alalawi, A., Almannai, N., et al. (2026) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.041.02.6171
“20,21 In our cohort, patients receiving combination therapy had higher baseline HbA1c levels, possibly reflecting the selection of individuals with more advanced or poorly controlled diabetes for more intensive treatment.”
Mortada, I., Lee, A. W., Buckingham, D., Quach, V., Rice, J., Mansour, S., Chatila, K., Shalaby, M., Jehle, D. V., Boyars, M. C., et al. (2026) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447261478928
Zhang, J., Shu, Q.-P., Tang, Y., Liu, H., Zhang, C., Chen, X., & Li, S. (2026) · Antioxidants · doi:10.3390/antiox15081025 · Cited by 1
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Ortiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Papastathopoulou, N. S., Neri, S., Assirelli, E., D’Amuri, A., Greco, S., Ciaffi, J., & Ursini, F. (2026) · Rheumatology Advances in Practice · doi:10.1093/rap/rkag105
Wartko, P. D., Zhang, R., Johnson, E., Begle, C., Bobb, J. F., Chen, C., Singh, A., ROSS, L. C., O’Connor, P. J., Arterburn, D. E., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113504
Falcão, L., Oliveira, L. D. B., Magalhães, P. L. M., Goyal, A., Maximiano, M. L. D. B., Donato, K. O., Silva, R. A. S., Gonzalez, J. V. P., da Silva, A. M. P., Corin, A. S., et al. (2026) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70131 · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“…receptor activation is mainly known to decrease appetite, delay stomach emptying, and enhance glucose-dependent insulin secretion, whereas GIP receptor activation might have additional effects on insulin secretion, adipose tissue metabolism, central appetite control, and energy balance [35,36].”
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
“…pathways confers distinct metabolic intervention characteristics in promoting weight loss, improving insulin sensitivity, and regulating energy metabolism, thus offering considerable therapeutic and developmental potential in obesity-or insulin resistance-https dominant MASH phenotypes [60–62].”
Zhang, J., Wang, J., Huang, W., Zhou, F., Wang, Z., Ren, X., Shenkman, B. S., & Ding, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.001
Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes
Liao, K., Kuo, C.-Y., Wu, J., Hsu, W., Tsai, Y., & Lai, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1928877
Chen, S.-C., Huang, Y., Li, P.-Y., Chen, J.-C., Meyerowitz‐Katz, G., Yang, S., & Su, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71266
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
“Further reinforcing this concept, novel incretin-based agents, tirzepatide (a dual glucose-dependent insulino-tropic polypeptide [GIP]/GLP-1 receptor agonist) and retatrutide (a triple GIP/GLP-1/glucagon receptor agonist), have demonstrated unprecedented glycemic and weight benefits [17–19].”
Wood, A. J., Lovegrove, C. E., Furniss, D., & Wiberg, A. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag173 · Cited by 1
Smith, C. R. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000055
Hassan, A., Farooq, Q. U. A., Parwesh, F., Rasul, M., Masood, A., Aftab, H., Riaz, H., Mahmood, A., Malik, M. A., Rehman, A. U., et al. (2026) · F1000Research · doi:10.12688/f1000research.186847.1
Paccola, G. P., de Oliveira, R. F., Mochetti, M. M., Razera, F. P. M., Vecchi, R., & Montanher, R. C. P. (2026) · Clinical Obesity · doi:10.1111/cob.70111 · Cited by 1
Davidson, M. B. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-03022-jc
Mikołajuk, A., Mallah, R., Kozdroń, D. J., Nieścioruk, M. W., Szczepańska, P., Kowalski, J., Dutkiewicz, D., & Yarbou, A. E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5581
Real-world Challenges and Predictors of Success in Glucagon-like Peptide-1 Receptor Agonist Therapy
Patankar, N. M., & Sanghvi, S. J. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1627
Sztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions
Elgindi, D., & Petronic-Rosic, V. M. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.012 · Cited by 1
Tripathi, A. P., Verma, M., Tripathi, M., & Singh, B. K. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012945
The promise of biased ligands in therapeutics
Eiger, D. S., Smith, J. S., & Rajagopal, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100160
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec3372
Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice
Miranda, D. D. A., de Arruda, J. A. A., & de Andrade, B. A. B. (2026) · Oral Diseases · doi:10.1111/odi.70484
Jóźwik-Szymańska, A., Kostecka, N., Mikula, L., Bogdan-Groszyk, Z., Szredzka, A., Kucharski, J., Makulec, A., Otrębska, K., & Lewandowska, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6514
“…reductions in both HbA1c and body weight than semaglutide, with the 15 mg dose achieving a mean body weight reduction of approximately 11.2 kg compared with 5.7 kg with semaglutide at 40 weeks, representing a difference of more than 5 kg between the two active agents alone (Frías et al., 2021).”
InfluentialDavis, S. C., Patel, S. V., Fletcher, S., McLaughlin, J. P., Deren, M. E., & Piuzzi, N. S. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.21203/rs.3.rs-10744245/v1 · Cited by 1
Buciuc, A. G., Gold, M. S., & Fuehrlein, B. (2026) · Addiction & Prevention · doi:10.3390/addictprev1010007
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
Андреев, Д. Н., & Kucheryavyy, Y. A. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.8.203814
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Bahnasy, S., Eladawi, S., Abdelaziz, M., Iyad, K., Kandil, A. H., Zinhom, K., Reyad, M., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70313
“Broader head- to-head evidence is directionally consistent, as SURPASS-2 demonstrated greater HbA1c reduction with TZP compared with semaglutide 1 mg, alongside a clear dose gradient across TZP doses [30].”
Cautela, D., Valeria, I., Lombardi, A., Laratta, B., Castaldo, C. M., Balestrieri, M. L., Mocini, E., Migliaccio, S., & Tardito, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188057
“GLP-1 and GIP are linear peptides derived from the proteolytic cleavage of the proglucagon and pro-GIP precursors, characterized by a specific amino acid sequence that allows them to bind to their respective G protein-coupled receptors (GPCRs) expressed on pancreatic β -cells [1,14,15].”
InfluentialCardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
Feng, Y., Sun, C., Li, X., Hu, L., Zhou, K., Li, L., Yuan, Y., Yu, L., Wu, M., & Liu, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1934027
Wu, K. A., Choudhury, A., Wu, J. A., Shenoy, D. A., Song, J., Mai, E., Dhanjani, S. A., Shatkin, M. S., Wellman, S. S., Seyler, T. M., et al. (2026) · The Knee · doi:10.1016/j.knee.2026.104639
Patel, D., Ewida, H. A., Tareq, S., Aziz, M. T., Chelikani, P. K., Bickel, U., & Ahmed, M. S. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00404
Myśliwczyk, D., Myśliwiec, M., Minarowska, A., & Wasilewska, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188191
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
“The results affirm the principle, observed with incretin-based therapies like tirzepatide, that robust receptor agonism translates into superior metabolic outcomes [32].”
Bawadi, H. A., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70338
Himanshu, Verma, S., Yadav, S., Singh, A., Chauhan, J., Sameeksha, Sahu, K., & Mamgain, A. K. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-026-00025-4
“Tirzepatide demonstrated HbA1c reductions of up to 2.4% and substantial weight reduction in the SURPASS clinical trials [69].”
InfluentialStewart, K. D., Matza, L. S., Chinthammit, C., Pavo, I. J., Bartee, A. K., & Boye, K. S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01907-y
Liu, D., Xie, D., Che, X., Li, X., Xu, W., & Wu, G. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108456
Brucar, L. R., Miller, K. M., & Volkow, N. D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106990
Ibraheem, M., Isazade, V., Zhang, N., Katariya, N., Kumar, A., Heilman, R. L., Nair, S. S., Mour, G. K., & Kodali, L. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.09.018
He, K., Wei, Y., Zhao, H., Zhang, L., Wu, F., Liu, R., Zhang, Y., Wang, Y., Chen, H., ZENG, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71218 · Cited by 1
Tu, C.-Y., Chen, H.-L., Wu, Y.-H., & Wu, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113573
Quantitative insights into tirzepatide and semaglutide using longitudinal systems modeling
Yang, B., Cabrera, O., Mather, K. J., & Sherman, A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag383
Ferician, A. C., Ghitea, T. C., & Popoviciu, M. S. (2026) · Medicina · doi:10.3390/medicina62091816
“…conventional GLP-1 receptor agonists, fixed-ratio insulin/GLP-1 combinations, and tirzepatide, which differ in molecular targets and formulation; subclass counts are reported, and this heterogeneity is an additional reason to avoid a class-wide mechanistic or causal interpretation [6,14–16].”
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.